# Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

> **NCT00654927** · PHASE3 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 177 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Fampridine-SR b.i.d. (Twice Daily)

## Key facts

- **NCT ID:** NCT00654927
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2011-01
- **Final completion:** 2011-04
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2012-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654927, "Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00654927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*